Abstract: Ovarian carcinosarcoma is a highly invasive malignant tumor, which is more common in postmenopausal women. The tissue contains both cancerous and sarcoma components, and the incidence is low. Early diagnosis is difficult, and most of the visits are late. Compared with epithelial ovarian cancer, it is more malignant, less sensitive to chemotherapy, and has a worse prognosis. Because of its relatively rare nature, it is difficult to conduct large-scale prospective clinical studies, making the establishment of systematic treatment guidelines a huge challenge. Current treatments are mostly based on retrospective studies or treatment experience of epithelial ovarian cancer. Tumor cytoreductive surgery is the main surgical treatment. Regarding postoperative adjuvant chemotherapy, there is no standardized chemotherapy regimen in the world. Most studies support platinum-based combination chemotherapy, the role of radiotherapy is uncertain, and targeted therapy is under further study.

Key words: Ovarian neoplasms, Carcinosarcoma, Histology, Therapy, Prognosis